Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2026 | Evaluating the future of 177Lu-PSMA-617 combination therapies in mCRPC

David Wise, MD, PhD, NYU Langone Health, New York, NY, comments on the potential of combining therapies to enhance the efficacy of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC), noting that while 177Lu-PSMA-617 often yields a strong initial response, disease progression can occur relatively quickly. Future combinations of 177Lu-PSMA-617 with other treatments, such as immunotherapy and radiation, will hopefully improve the durability of responses. This interview took place at the 2026 ASCO GU Cancers Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Our vision is that this combination is going to potentiate response to Pluvicto and improve durability. That’s really been the major, I would say, limitation of Pluvicto is that it gives a great initial response, but we see progression fairly quickly. And the goal here is that this could be an I/O radiation combo, which will give us actually much better durability...

Our vision is that this combination is going to potentiate response to Pluvicto and improve durability. That’s really been the major, I would say, limitation of Pluvicto is that it gives a great initial response, but we see progression fairly quickly. And the goal here is that this could be an I/O radiation combo, which will give us actually much better durability. That’s really what we’re going to be presenting at subsequent conferences.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...